Connect Sign InTherapeutic drug monitoring (TDM) of thiopurine drugs
Thiopurine drugs are prescribed to treat patients with acute lymphoblastic leukemia, autoimmune diseases and inflammatory bowel disease. Thiopurine drugs must be metabolized to pharmacologically active metabolites in order to exert its effects. The amount of active metabolites is regulated by the enzyme, thiopurine methyltransferase, which functions to inactivate about 90% of the drug dose to balance the formation of active metabolites. Individuals with low TPMT activity are unable to inactivate the drug methylation and these individuals are at risk for bone marrow toxicity, if they receive standard dose therapy. Therefore, TPMT activity should be assessed prior thiopurine drug administration.
Dr. Johnson-Davis is an associate professor (clinical) at the University of Utah School of Medicine. She received her BS in biochemistry from the University of California, Riverside, and her PhD in pharmacology from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology and completed a postdoctoral fellowship in clinical chemistry at the University of Utah Department of Pathology. Dr. Johnson-Davis is board certified in clinical chemistry and toxicological chemistry. She is a diplomate of the American Board of Clinical Chemistry and a fellow of the National Association of Clinical Biochemistry and the Association of Clinical Scientists.
